On July 2, 2015, the
White House issued an executive memorandum directed towards the FDA, EPA, and USDA,
requiring modernization of their biotechnology regulations.
The order states the
existing regulations adequately protect health and safety, but there are “…in
some cases, unnecessary costs and burdens associated with uncertainty about
agency jurisdiction, lack of predictability of timeframes for review, and other
processes…” These uncertainties have
created difficulties for both small and mid-sized companies as well as the
public to understand the regulatory process and food safety. The memorandums objective is to ensure public
confidence and prevent “unnecessary barriers to future innovation and
competitiveness by improving transparency, coordination, predictability, and
efficiency of the regulation of biotechnology products…”
The memorandum requires
an updated federal Coordinated Framework for the Regulation of Biotechnology (CF) within a year of the memorandum issue date. The CF provides the outline for the federal
regulatory policy that ensures the safety of biotechnology products. Updating the CF could clarify each agency’s
role in biotechnology regulation as well as create a long-term strategy to
ensure inadequacies in the current system are addressed.
The group
responsible for updating the CF will be a “new Biotechnology Working Group under
the Emerging Technologies Interagency Policy Coordination Committee (ETIPC).” The Working Group will have representatives
from the Executive Office of the President, EPA, FDA, and the USDA. Further, the EPA, FDA, and USDA are
required to have an external, independent analysis of “the future landscape of
biotechnology” every five years in order to make informed policy decisions due
to biotechnology products and processes rapid changes.
Written by Katharine Richter - Research Assistant
July 3, 2015
No comments:
Post a Comment